Hepatitis C: Home Page

<body><!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"> <html xmlns="http://www.w3.org/1999/xhtml"> <head><link rel="stylesheet" media="print" href="https://www.ark.org/siteheader/print.css" type="text/css" /> <style type="text/css"> @media print { #banner, #topnav, #logo, #empty, #arlogo, .noprint { display: none; } } @media screen { #banner { margin-top:0px; margin-left:0px; margin-right:0px; } } </style> <style type="text/css"> body {font-size:100%; margin:0px; padding:0px;} #banner{ background-color: #FFFFFF; width: 100%; height: 30px; border-bottom: 1px solid #747A7C; padding:0px; margin:0px;} #topnav{ margin-top:-18px; font-family: Arial; text-align:right; color: #747A7C; background-color: transparent; font-size: 11px; position:relative; text-decoration:none; font-weight: bold; padding-right:10px;} #topnav a:link { text-align:right; color: #747A7C; background-color: transparent; font-size: 11px; text-decoration:none;} #topnav a:visited {text-align:right; color: #747A7C; background-color: transparent; font-size: 11px; text-decoration:none;} #topnav a:hover { text-align:right; color: #747A7C; background-color: transparent; font-size: 11px; text-decoration:underline;} #topnav a:active { text-align:right; color: #747A7C; background-color: transparent; font-size: 11px;text-decoration:none;} #logo { background-color: #FFFFFF; width:100px; height:25px; position:relative; margin:0px; padding-left:10px; padding-top:4px; padding-bottom:-3px; } #empty{ height: 3px; width: auto;} </style> </head> <body topmargin="0" leftmargin="0" bottommargin="0"><div id="banner"><div id="logo"><a href="http://www.arkansas.gov"><img src="https://www.ark.org/siteheader/argovlogo_v2.gif" alt="Arkansas.gov" width="106" height="25" border="0"></a></div></div><div id="topnav"><a href="http://www.arkansas.gov/government_name.php">Agencies</a> | <a href="http://www.arkansas.gov/online_services_alpha.php">Online Services</a> | <a href="http://www.arkansas.gov/ina_policy.php">Policies</a></div></div> <div id="empty"> </div></body> </html> <table border="0" width="553" cellspacing="0" cellpadding="00"> <tr> <td width="578"><img src="../graphics/06_manage.jpg" alt="06_manage.jpg (22736 bytes)" width="555" height="70"><div align="right"><table border="0" width="556" cellspacing="0" cellpadding="0"> <tr> <td width="125" valign="top"></td> <td width="366" valign="top"></td> </tr> <tr> <td width="125" valign="top"><p align="center"><br> <img src="../graphics/05_photo.jpg" alt="05_photo.jpg (9881 bytes)" WIDTH="105" HEIGHT="223"></td> <td width="366"><table border="0" width="425" cellspacing="0" cellpadding="0"> <tr> <td width="413"><br> <img src="../graphics/05_quote.jpg" alt="05_quote.jpg (15884 bytes)" WIDTH="411" HEIGHT="73"><a name="top"></a><p> </td> </tr> <tr> <td width="413" ><font face="Verdana, Arial, Helvetica" size="2">HCV-positive patients should be evaluated for the presence and severity of chronic liver disease.  Initial evaluation for presence of disease should include multiple measurements of ALT at regular intervals, because ALT activity fluctuates in persons with chronic hepatitis C. Patients with chronic hepatitis C should be evaluated for the severity of their liver disease and for possible treatment. </font><p><font face="Verdana, Arial, Helvetica" size="2">Antiviral therapy is recommended for patients with chronic hepatitis C who are at greatest risk for progression to cirrhosis. These persons include anti-HCV-positive patients with persistently elevated ALT levels, detectable HCV RNA, and a liver biopsy that indicates either portal or bridging fibrosis or at least moderate degrees of inflammation and necrosis.</font></p> <p><font face="Verdana, Arial, Helvetica" size="2">In patients with less severe histologic changes, indications for treatment are less clear, and careful clinical follow-up might be an acceptable alternative to treatment with antiviral therapy (e.g., interferon) because progression to cirrhosis is likely to be slow, if it occurs at all.  Similarly, patients with compensated cirrhosis (without jaundice, ascites, variceal hemorrhage, or encephalopathy) might not benefit from interferon therapy. Careful assessment should be made, and the risks and benefits of therapy should be thoroughly discussed with the patient.</font></p> <p><font face="Verdana, Arial, Helvetica" size="2">Patients with persistently normal ALT values should not be treated outside of clinical trials, as treatment might actually induce liver enzyme abnormalities. Patients with advanced cirrhosis who might be at risk for decompensation with therapy and pregnant women also should not be treated. Interferon treatment is not FDA-approved for patients aged <18 years or >60 years. Treatment of patients who are drinking excessive amounts of alcohol or who are injecting illegal drugs should be delayed until these behaviors have been discontinued for <u>></u> 6 months. Contraindications to treatment with interferon include major depressive illness, cytopenias, hyperthyroidism, renal transplantation, and evidence of autoimmune disease. </font></p> <p><font face="Verdana, Arial, Helvetica" size="2">Most clinical trials of treatment for chronic hepatitis C have been conducted using alpha interferon. When the recommended regimen of 3 million units administered subcutaneously 3 times/week for 12 months is used, approximately 50% of treated patients have normalization of serum ALT activity (biochemical response), and 33% have a loss of detectable HCV RNA in serum (virologic response) at the end of therapy.  However, <u>></u> 50% of these patients relapse when therapy is stopped. Thus, 15%-25% have a sustained response as measured by testing for ALT and HCV RNA <u>></u> 1 years after therapy is stopped, many of whom also have histologic improvement. For patients who do not respond by the end of therapy, retreatment with a standard dose of interferon is rarely effective.  Patients who have persistently abnormal ALT levels and detectable HCV RNA in serum after 3 months of interferon are unlikely to respond to treatment, and interferon treatment should be discontinued. These persons might be considered for participation in clinical trials of alternative treatments. Decreased interferon response rates (<15%) have been found in patients with higher serum HCV RNA titers and HCV genotype 1 (the most common strain of HCV in the United States); however, treatment should not be withheld based solely on these findings.</font></p> <p><font face="Verdana, Arial, Helvetica" size="2">Therapy for hepatitis C is a rapidly changing area of clinical practice. Combination therapy with interferon and ribavirin, a nucleoside analogue, is approved for the naive treatment of patients with chronic hepatitis C. Studies of patients treated with a combination of ribavirin and interferon have demonstrated a substantial increase in sustained response rates, reaching 40%-50%, compared with response rates of 15%-25% with interferon alone. However, as with interferon alone, combination therapy in patients with genotype 1 is not as successful, and sustained response rates among these patients are still <30%. </font></p> <p><font face="Verdana, Arial, Helvetica" size="2">Most patients receiving interferon experience flu- like symptoms early in treatment, but these symptoms diminish with continued treatment. Later side effects include fatigue, bone marrow suppression, and neuropsychiatric effects (e.g., apathy, cognitive changes, irritability, and depression). Interferon dosage must be reduced in 10%-40% of patients and discontinued in 5%-15% because of severe side effects. Ribavirin can induce hemolytic anemia and can be problematic for patients with pre-existing anemia, bone marrow suppression, or renal failure. In these patients, combination therapy should be avoided or attempts should be made to correct the anemia. Hemolytic anemia caused by ribavirin also can be life-threatening for patients with ischemic heart disease or cerebral vascular disease. Ribavirin is teratogenic, and female patients should avoid becoming pregnant during therapy.</font></p> <p><font face="Verdana, Arial, Helvetica" size="2">Other treatments, including corticosteroids, ursodiol, and thymosin, have not been effective. High iron levels in the liver might reduce the efficacy of interferon.  Use of iron reduction therapy (phlebotomy or chelation) in combination with interferon has been studied, but results have been inconclusive. Because patients are becoming more interested in alternative therapies (e.g., traditional Chinese medicine, antioxidants, naturopathy, and homeopathy), physicians should be prepared to address questions regarding these topics.</font><a name="top"></a></p> <p><font SIZE="2"></font><a href="http://www.niddk.nih.gov/health/digest/pubs/chrnhepc/chrnhepc.htm" target="_self"><font size="2" face="Verdana, Arial, Helvetica">Click here </font></a> <font size="2" face="Verdana, Arial, Helvetica"> for recommendations from the National Institutes of Health (NIH) on the treatment of chronic hepatitis C. </font></p> <p align="left"><strong><font color="#400000"><br> </font><font face="Verdana, Arial, Helvetica"><a href="javascript:sq()"><img src="../graphics/question_click.jpg" alt="0_study questions.jpg (6027 bytes)" border="0" width="421" height="50"></a></font></strong></p> </td> </tr> <tr> <td width="413" > <div align="right"> <table border="0" cellpadding="2" cellspacing="0"> <tr> <td nowrap><a href="javascript:history.go(-1);back()"><img border="0" src="../graphics/back.jpg" alt="BACK" width="42" height="29"></a><img border="0" src="../graphics/fill.jpg" width="42" height="29"><img border="0" src="../graphics/open.jpg" width="26" height="29"><a href="../5/default.htm" target="_top"><img border="0" src="../graphics/next.jpg" alt="NEXT" width="45" height="29"></a></td> </tr> </table> </div> </td> </tr> </table> </td> </tr> </table> </div></td> </tr> </table> </body>